UNMATCHED SUPPLY CHAIN SOLUTIONS FOR THE LIFE SCIENCES INDUSTRY

654
Active Clinical Trials
10
Commercial Products
625,000+
Shipments
150+
Countries
Box-for-4Q2022 
2022’s Data ManagementTransitionsWebinar

2022’s Data Management Transitions Webinar

Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?

  • How will capacity and connectivity challenges impact carrier services and packaging technology providers?
  • How can you guarantee the certainty of global coverage and data fidelity for your cell and gene therapy shipments?
WATCH NOW
Download our ISO 21973 White Paper

Download our ISO 21973 White Paper

A leap forward in standardizing the regenerative medicine supply chain

  • Ensuring full compliance at every step in the transportation process
  • Standardization at scale
  • Mitigating risk in a zero failure environment
LEARN MORE

The Latest From Our Blog View All

Innovation and Risk Mitigation are Priorities for Cell&Co BioServices

At Cell&Co BioServices, a Cryoport Systems company, new product innovations are not adopted without significant testing. Recently our team dedicated 3 months to the creation and certification of a new type of cryogenic freezer technology.

State of the Industry: 2023 Predictions with Dr. Mark Sawicki

Cryoport Systems has grown to become a leader in the cell and gene therapy industry since its founding in 1999. Throughout those 20+ years, we've seen how both the growth and transformation of the market has continually created new life-saving therapies for patients in need. This innovation is particularly true of the modern advancements seen in the last few years.  

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

Cryoport Systems has officially launched our BioServices solutions through our two new Global Supply Chain Centers. Learn More